________________________________________________________________________________________________________________________
and minimize the impact of a disruption. There is not a‘ one size fits all’ approach, as supply chain resiliency strategy is determined based on product criticality, market availability, and source region. Unfortunately, in many cases, added resilience increases cost to the healthcare system.”
Navigating challenging times
In 2024, the healthcare industry faced a significant product shortage of Baxter intravenous( IV) fluids. Although allocations have been in place for years for many fluids, it was further complicated by Hurricane
Our overarching goal is to provide best-inclass, highly reliable care that is delivered with extraordinary service
Helene hitting Baxter’ s manufacturing facility in North Carolina. As the largest manufacturer of IV fluid in the US, Baxter produces around 60 percent of the fluid used in the US, and its production halt meant more than 86 percent of healthcare providers experienced shortages.
“ Aside from the Covid-19 pandemic, the Baxter IV shortage has been the most impactful supply challenge we’ ve faced, but the expertise of our clinical, pharmacy, and supply chain teams has enabled us to manage the situation,” Mike shares.“ There are a
88